FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for OZURDEX (dexamethasone) by Allergan, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema Following Branch Retinal Vein Occlusion
• Macular Edema Following Central Retinal Vein Occlusion
• Noninfectious Posterior Segment Uveitis

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

SUPPL AP for OZURDEX (DEXAMETHASONE)